PAVmed Inc. Common Stock
PAVMPAVmed Inc. (PAVM) is a medical technology company focused on developing and commercializing innovative healthcare products. The company emphasizes minimally invasive solutions across various medical specialties, including diagnostics, devices, and digital health, aiming to improve patient outcomes and reduce healthcare costs.
Company News
PAVmed Inc. announced a 1-for-30 reverse stock split effective January 2, 2026, to comply with Nasdaq's $1.00 minimum bid price requirement. The split was approved by stockholders on December 5, 2025, and authorized shares will be reduced from 250 million to 25 million. The company's stock will continue trading under symbol PAVM on Nasdaq Capital...
Lucid Diagnostics will host a business update conference call on November 12, 2025, at 8:30 AM ET, where CEO Lishan Aklog will discuss company operations and growth strategy, and CFO Dennis McGrath will review Q3 2025 financial results.
Lucid Diagnostics, a cancer prevention medical diagnostics company, announced plans for a public stock offering to support working capital and general corporate purposes, with Canaccord Genuity LLC and BTIG, LLC acting as joint bookrunners.
PAVmed, a diversified medical technology company, will host a business update conference call and webcast on November 14, 2024, to discuss its third quarter 2024 financial results and provide an overview of its operations and growth strategy.
PAVmed Inc. (PAVM) closed at $2.07 in the latest trading session, marking a -1.43% move from the prior day.
